Genmab reported 264M in Selling and Administration Expenses for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Agios Pharmaceuticals AGIO:US $ 29.22M 4.34M
Alexion Pharmaceuticals ALXN:US $ 342.9M 101.5M
Amarin AMRN:US 107.2M 1.4M
Amgen AMGN:US $ 1.38B 130M
AstraZeneca AZN:LN 2.57B 76M
Bayer BAYN:GR 3.75B 226M
Biomarin Pharmaceutical BMRN:US $ 184.16M 9.84M
Bluebird Bio BLUE:US $ 78.58M 8.3M
Exelixis EXEL:US $ 98.49M 3.86M
Fresenius Medical Care FME:GR 830M 118M
Galapagos GLPG:NA 60.95M 15.96M
Genmab GEN:DC 264M 63M
GlaxoSmithKline GSK:LN 2.5B 183M
GN Store Nord GN:DC 1.11B 18M
GRIFOLS GRF:SM 249.86M 7.28M
H. Lundbeck A/S LUN:DC 1.58B 79M
Hikma Pharmaceutical HIK:LN 232M 3M
Immunogen IMGN:US $ 9.73M 481K
Insmed INSM:US $ 57.18M 5.63M
Merck MRK:GR 1.34B 62M
Novartis NOVN:VX 3.71B 190M
Regeneron Pharmaceuticals REGN:US $ 414.7M 9.1M
Seattle Genetics SGEN:US $ 165.13M 5.29M
William Demant Holding WDH:DC 4.48B 503M